BP16 clinical trials

A Phase III, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of BP16 Versus EU-Prolia® in Women with Post- Menopausal Osteoporosis

This study compares a new medicine (BP16) with an existing one (Prolia®) for women with weak bones after menopause. Researchers will check if BP16 helps strengthen bones, how safe it is, and if the body reacts to it, over about a year and a half.